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Summary
Background The frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and there is no 
standard test. Asymptomatic infection with Ebola virus could contribute to population immunity, reducing spread. If people 
with asymptomatic infection are infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact.
Methods We validated a new oral fluid anti-glycoprotein IgG capture assay among survivors from Kerry Town Ebola 
Treatment Centre and controls from communities unaffected by EVD in Sierra Leone. We then assessed the seroprevalence 
of antibodies to Ebola virus in a cross-sectional study of household contacts of the survivors. All household members were 
interviewed. Two reactive tests were required for a positive result, with a third test to resolve any discrepancies.
Findings The assay had a specificity of 100% (95% CI 98·9–100; 339 of 339 controls tested negative) and sensitivity of 
95·9% (89·8–98·9; 93 of 97 PCR-confirmed survivors tested positive). Of household contacts not diagnosed with 
EVD, 47·6% (229 of 481) had high level exposure (direct contact with a corpse, body fluids, or a case with diarrhoea, 
vomiting, or bleeding). Among the contacts, 12·0% (95% CI 6·1–20·4; 11 of 92) with symptoms at the time other 
household members had EVD, and 2·6% (1·2–4·7; 10 of 388) with no symptoms tested positive. Among asymptomatic 
contacts, seropositivity was weakly correlated with exposure level.
Interpretation This new highly specific and sensitive assay showed asymptomatic infection with Ebola virus was 
uncommon despite high exposure. The low prevalence suggests asymptomatic infection contributes little to herd 
immunity in Ebola, and even if infectious, would account for few transmissions.
Funding Wellcome Trust ERAES Programme, Save the Children.
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Introduction
It is not known how frequently asymptomatic Ebola virus 
infection occurs, yet it could affect the course of epidemics. 
High rates of asymptomatic infection would reduce 
incidence through herd immunity, radically altering model 
predictions of epidemic spread.1 If those with asymptomatic 
infection are infectious, perhaps with persistent viral 
shedding, it would help explain some failures in control 
and the emergence of new chains of transmission.2
The extent of asymptomatic infection is unclear because 
previous findings have varied widely (eg, from 1% to 46% 
of household contacts),3,4 with positive results reported in 
some populations unlikely to have been exposed to 
filoviruses.5–7 This finding has led to questions about 
assay specificity and cross-reactivity for ELISAs as well as 
for the older immunofluorescence antibody techniques. 
There is no assay approved by the US Food and 
Drug Administration, and the need for caution in inter-
preting Ebola virus antibody serosurveys continues to be 
emphasised.8
A reliable serological test could also help identify missed 
cases with minor symptoms. Asymptomatic infections 
and missed symptomatic cases might explain the apparent 
lower incidence of Ebola virus disease (EVD) in children.9,10 
Diagnosis might be missed in young children,11 and older 
children could be less susceptible to developing EVD if 
infected.12
A test for Ebola virus antibodies with high sensitivity and 
specificity is needed. Taking blood is difficult in an Ebola 
epidemic, due to both the infection risk and population 
suspicion. We describe the field validation of a new capture 
ELISA that detects IgG to Ebola virus glycoprotein in oral 
fluid,13 and the results of a large seroprevalence study in 
Ebola-affected households.
Methods
Participants and data collection
All survivors from Kerry Town Ebola Treatment Centre, 
Sierra Leone, who were discharged between Nov 22, 
2014, and March 27, 2015, and their household members 
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(people eating from the same pot), were sought for this 
study. Interviews were done between July 3, 2015, and 
Sept 10, 2015, encouraging household members to tell 
their story as a group, as described elsewhere.12 For each 
person in the household who was ill or died of EVD we 
asked who had helped them and had contact with them. 
We also asked about exposures outside the household. 
With additional probing questions, we established the 
maximum exposure level for each person, including 
those who had not been ill and those who had died, 
using predefined levels.12 The highest level was touching 
the body of someone who died of EVD, then direct 
contact with body fluids of a wet case (ie, an EVD case 
with diarrhoea, vomiting, or bleeding); direct contact 
with a wet case (including nursing and personal care, 
sharing a bed); direct contact with a dry case (ie, an EVD 
case without wet symptoms); indirect contact with a wet 
case (eg, washing clothes or bed linen); indirect contact 
with a dry case; minimal contact (eg, shared meals); and 
no known contact.
Individuals who did not report EVD were asked about 
symptoms at the time that others in the household had 
EVD. Those reporting symptoms were classified using 
the Sierra Leone case definition for probable EVD14 
(ie, either contact plus fever or miscarriage or unexplained 
bleeding, or contact plus three or more symptoms 
[of fatigue, headache, loss of appetite, nausea or vomiting, 
abdominal pain, diarrhoea, muscle or joint pain, sore 
throat or pain on swallowing, and hiccups]).
Swabs (Oracol, Malvern Medical Developments, 
Worcester, UK) for oral fluid collection were demonstrated 
by the field staff and then self-administered, with adults 
helping children. Each swab was rubbed firmly on the 
gums for 90 s, sealed, put in a cool box, and transferred 
daily to a –20°C freezer for storage before processing.
Additionally, we recruited community controls in 
three neighbourhoods of rural Western Area, 
Sierra Leone, without known EVD cases (Kent, Tokeh, 
and York). Community leaders with megaphones asked 
for volun teers of all ages, and we then excluded any with 
exposure to Ebola and collected oral swabs as described 
above.
Individual written informed consent was obtained 
from all participants (or their parents or guardians for 
those younger than 18 years) before interview and sample 
collection. Permission for the study was granted by the 
Sierra Leone Ethics and Scientific Review Committee 
and the Ethics Committee of the London School of 
Hygiene & Tropical Medicine.
Procedures
Oral fluid samples were tested for Ebola virus glycoprotein 
IgG using a new IgG capture assay based on the EBOV 
Mayinga GP antigen (rGPδTM [catalogue 0501-016]; IBT 
Bioservices, Rockville, MD, USA) as described elsewhere.13 
Two positive controls (plasma from a UK EVD survivor 
infected in Sierra Leone) and four negative controls 
(plasma from UK donors) were included in each plate. 
The cutoff for a reactive result was defined per plate as the 
mean optical density (OD) of the negative controls plus a 
fixed OD measure (0·1). Since the mean negative OD 
varied between 0·049 and 0·067 per plate, this is 
equivalent to 2·5–3 times the mean negative OD. We 
present normalised ODs (ie, the ratio of the test OD to the 
cutoff), so results greater than 1 were reactive. All reactive 
samples from household members and controls, all 
Research in context
Evidence before this study
We did a systematic review of studies of seroprevalence of 
antibodies to Ebola virus. We searched PubMed and Web of 
Science using the search string “ebola AND (asymptom* OR 
antibod* OR IgG OR immun* OR ELISA OR serol*) NOT vacc* 
NOT immuniz* AND (Humans[Mesh])”, as well as reference lists 
(including those of previous reviews) and conference reports 
from the west Africa epidemic. We last updated the search on 
July 31, 2016, and used no language restrictions. 
Different assays have been used and the specificity of the tests 
is frequently questioned. Of 50 studies, only six reported results 
for asymptomatic household contacts, with varying prevalence 
estimates: 2·5% in the first known Ebola virus outbreak using 
an immunofluorescence assay; and 1·0% in Uganda, 4·0% in the 
Democratic Republic of Congo, 6·5% in Sierra Leone, and 21·4% 
and 45·9% in Gabon, using different ELISAs.
Added value of this study
We present the first field validation of a new assay. It had 
very high specificity and sensitivity and has the added 
advantage of being non-invasive so was well accepted. Using 
this assay we showed that the prevalence of seropositivity to 
Ebola virus in asymptomatic household contacts, many of 
whom were highly exposed, was only 2·6%. Additionally, 
12% of contacts with some symptoms but never diagnosed 
with Ebola virus disease were seropositive. In these 
Ebola-affected households, asymptomatic infections 
accounted for 2·3% and missed symptomatic infections 
for 2·6% of all Ebola virus infections.
Implications of all the available evidence
Asymptomatic infection with Ebola virus occurs but given the 
low seroprevalence seen even in highly exposed individuals, 
it would not be a major contributor to herd immunity. 
The availability of a reliable non-invasive assay that is easy to 
administer and highly acceptable in the field will greatly aid 
future investigations and interventions, including testing and 
targeting of vaccines.
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unreactive samples from survivors, and a selection of 
other samples including those closer to the cutoff, were 
repeated. Samples with discrepant results were retested.
Using this assay, results from paired oral fluid and 
plasma samples have previously been shown to correlate 
well in 76 participants in an early phase Ebola vaccine 
trial in the UK (r=0·68, p<0·0001, two-tailed non-
parametric Spearman’s correlation);13 ten EVD survivors 
tested in Connaught Blood Bank, Sierra Leone (r²=0·83, 
linear regression); and 80 EVD survivors from Sierra 
Leone tested in the UK (r²=0·78, linear regression) 
(Tedder RS, unpublished). Using the same cutoff as in 
our study, 78 of 80 samples from the EVD survivors were 
positive on serum, of which 76 were positive on oral 
fluid, giving a sensitivity compared with serum of 
97·4% (76 of 78 samples). The two samples negative on 
both oral fluid and plasma were also negative on 
competitive and double-antigen bridging ELISAs. 
Additionally, 44 paired oral fluid and plasma samples 
from individuals not exposed to Ebola from The Gambia 
were negative on the capture ELISA using the same 
protocol (Tedder RS, unpublished).
527 household members 168 survivors 238 EVD deaths
431 well
38 not 
swabbed
4 swabs
excluded
2 not 
swabbed
1 not 
swabbed
1 swab
excluded
6 not 
swabbed
1 swab
excluded
9 not 
swabbed
35 some
symptoms
151 Kerry Town survivors
1 refused participation
27 were unavailable
8 lived outside Western Area
3 died after discharge
12 unable to make contact
2 had bad relations with household
1 no family in Western Area
1 unreceptive to previous contact
4 excluded (cause of death unclear)
2 elderly >85 years
1 possibily non-EVD obstetric complications
1 died after family had EVD
123 Kerry Town survivors
937 total household members at time of EVD in household
933 in population analysed
19 case definition
symptoms
and negative
test
42 case definition
symptoms 
and no test
123 Kerry Town 45 other Ebola
treatment
centres
227 confirmed
or reported
EVD deaths
11 probable 
EVD death
(case 
definition)
663 controls
116 people
112 positive
including
19 single
reactive
tests
4 negative
36 people
31 positive
including
2 single
reactive
tests
5 negative
339 people
0 positive
339 negative
389 people
10 positive
378 negative
1 indeter-
minate
33 people
7 positive
26 negative
19 people
0 positive
19 negative
40 people
4 positive
36 negative
Figure 1: Flow chart of study participants
Households were defined as those who ate from the same pot. They included everyone who stayed there at the time Ebola was in the household, including those who were not normally resident. Of those not 
swabbed, most were absent; eight refused (all had been asymptomatic) and four had died since Ebola. Of the six excluded swabs, three were miscoded and three were not found. EVD=Ebola virus disease.
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Statistical analysis
We assessed the sensitivity and specificity of the assay 
under field conditions using samples from PCR-
confirmed Kerry Town EVD survivors and from the 
community controls.
For further analyses, individuals were defined as having 
been infected if their sample was reactive on two or more 
tests, uninfected if their sample was unreactive on one or 
more tests, and indeterminate if their sample had an equal 
number of reactive and unreactive tests. Two reactive tests 
were required to define infection to maximise specificity 
and hence positive predictive value, which is important 
because the prevalence of asymptomatic infection could be 
low. The CIs for the proportion positive were calculated 
using exact methods because of small numbers.
We assessed risk factors for infection among asympto-
matic and symptomatic household members using χ² or 
Fisher’s exact test as appropriate. We assessed con-
found ing by age using logistic regression; further 
multivariable analysis was limited by the small number 
of events. Linear regression was used to assess the 
association of level of reactivity in the samples from 
survivors with time since admission and with age.
Data sharing
The raw data for this study are available online, by request. 
Role of the funding source
The sponsor of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
The households of 123 of 151 Kerry Town survivors were 
included in the study. One survivor had subsequently 
died15 but the household included another survivor so 
was visited. Of the remaining survivors, eight lived 
outside Western Area, three had died,15 16 were un-
available or uncontactable, and one refused to take part 
(figure 1).
The participating Kerry Town survivors lived in 
91 households with 814 other household members, 
of whom 242 had died (227 from EVD, 11 from probable 
EVD, and four from unknown causes [who were 
excluded from further analyses]) and 45 were survivors 
from other facilities (figure 1). Of the 527 other 
household members, 96 had some symptoms around 
the time others in their household had EVD and 
431 were asymptomatic. We collected 639 oral swabs 
from 153 survivors and 486 living household members, 
of which 633 (99·6%) could be analysed; only 
eight people (1·2%) refused to give a swab (figure 1). 
The mean age of the household members was 16·7 years 
(SD 14·2, range <1–84); 57% were female. The age and 
sex distribution of participating survivors and household 
members was similar to non-participants.
Oral swabs were collected from 663 community 
controls. Three people with possible Ebola virus exposure 
(two Ebola intervention workers and one funeral attendee) 
were excluded. Due to availability of test kits, we analysed 
the first 113 samples from each setting giving a total of 
339 (mean age 19·0 years [SD 15·6, range <1–76], 
53% female).
The distribution of normalised ODs (NODs) in the Kerry 
Town survivors and the community controls in the first 
test is shown in figure 2. From the Kerry Town survivors, 
113 (97·4%) of 116 samples were reactive on the first test. 
97 samples were retested: the three unreactive samples 
remained unreactive; one reactive sample was unreactive 
on retesting and on a third test (NODs 1·59, 0·97, 
and 0·69), and was considered negative; another reactive 
sample was unreactive on retesting and reactive on the 
third test (NODs 2·50, 0·76, and 1·01), and considered 
positive. All remaining initially reactive samples were 
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Figure 2: Normalised optical densities of the first test in samples from 116 Kerry Town survivors and 339 Sierra Leone controls
For the raw data see http://doi.
org/10.17037/DATA.41
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repeatedly reactive and considered positive (table 1). 
Defining positive as two reactive tests gives a sensitivity of 
95·9% (95% CI 89·8–98·9; 93 of 97 samples; table 2).
Among the community controls, all but one sample 
were unreactive on the initial test (338 [99·7%] of 
339 samples). This sample was unreactive on second and 
third tests (NODs 1·41, 0·33, and 0·32). There were no 
further reactive results among 25 samples that were 
retested. Since no control sample was considered positive, 
specificity was 100% (95% CI 98·9–100).
Among those with duplicate tests, NODs were in good 
agreement in the different participant groups (appendix 
pp 2–4). Overall, comparison of the NODs of the first and 
second test using linear regression, gave an r² of 0·88.
Among the survivors from other treatment centres (for 
whom we did not have documented evidence of positive 
Ebola virus PCRs) 31 (86·1%) of 36 samples were positive 
for Ebola IgG. 40 (8·3%) of 481 samples from household 
contacts without diagnosed EVD were reactive on the first 
test. After subsequent tests, 21 were considered positive, 
18 negative, and one indeterminate (table 1, appendix p 5). 
Among 389 asymptomatic contacts, ten (2·6%) of 388 were 
sero positive, compared with 11 (12·0%) of 92 sympto matic 
contacts (p=0·004). The asympto matic infec tions were 
from different households, whereas two people with 
symptomatic undiagnosed infections were from the same 
household.
Asymptomatic infection was only seen in those older 
than 12 years. By contrast, among symptomatic contacts, 
seropositivity was highest in children younger than 
5 years (four [26·7%] of 15) and in adults 30 years or older 
(six [35·3%] of 17) but undetected in teenagers and young 
adults (aged 10–29 years; table 3).
Level of exposure to Ebola correlated with seropositivity 
among asymptomatic and symptomatic contacts (table 3). 
Of the 12 individuals with direct contact with an EVD 
corpse who were not diagnosed with EVD themselves, 
four (33·3%) were infected, two asymptomatically. 
Among the 229 without known EVD with the three 
highest exposure levels (contact with corpse, body fluids, 
or wet cases), 16 (7%) were infected, seven asympto-
matically. There were few socioeconomic factors 
associated with positivity (table 3). Associations with 
occupation and being household head were explained by 
age. 23 contacts had spouses who were EVD survivors so 
could potentially have been infected by sexual trans-
mission after recovery. Two of these contacts were 
seropositive; both were male and had been symptomatic.
Among symptomatic contacts, neither the number of 
symptoms nor any individual symptom in the case 
definition, were associated with seropositivity, except for 
a non-significant correlation with red eyes (p=0·07; data 
not shown). The 11 seropositive undiagnosed 
symptomatic individuals were: a 1-year-old child with 
multiple symptoms who was not tested or admitted 
because of a nurses’ strike; a 2-year-old child and a 
9-year-old child with multiple symptoms who were not 
taken to a facility; three people with two symptoms 
(headache plus fatigue, loss of appetite or muscle or 
joint pain); and five people with single symptoms 
(abdominal pain, red eyes, hiccups, fever, or headache).
Overall, in these households there were 168 survivors 
and 238 EVD deaths reported at interview (figure 1), so 
Total Positive Negative Indeterminate IgG 
positive/total*
IgG positive 
(95% CI)
RR R RUR RUU UUU UU U RRUU
Community controls 339 0 0 0 1 0 25 313 0 0/339 0·0% (0–1·08)
Kerry Town survivor 116 92 19 1 1 2 1 0 0 93/97 95·9% (89·8–98·9)
Household member: survivor from other Ebola 
treatment centre
36 29 2 0 0 2 3 0 0 29/34 85·3% (68·9–95·0)
Household member: asymptomatic 389 10 0 0 17 8 76 277 1† 10/388 2·6% (1·2–4·7)
Household member: symptomatic 92 10 0 1 1 2 8 70 0 11/92 12·0% (6·1–20·4)
Symptoms fitting case definition/no PCR test 40 3 0 1 1 1 3 31 0 4/40 10·0% (2·8–23·7)
Symptoms fitting case definition/PCR negative 19 0 0 0 0 1 0 18 0 0/19 0·0% (0–17·6)
Symptomatic not fitting case definition 33 7 0 0 0 0 5 21 0 7/33 21·2% (9·0–38·9)
Because of limited availability of kits, not all samples could be retested. We retested all positives (except some from known survivors of Ebola virus disease but including all those nearer the cutoff), all negatives 
from EVD survivors, and a sample of other negatives, prioritising those nearer the cutoff. We did third tests on any samples with discrepant results after two tests. For those samples with only one previous result, 
which were retested on the last available plate, we retested in duplicate in case any discrepancies arose. R=reactive. U=unreactive. *Total individuals; those with only a single reactive test available or 
indeterminate results excluded. †Retested because of borderline results; mean of all normalised optical densities 1·0 (SD 0·4; appendix p 5).
Table 1: Prevalence of Ebola IgG positivity in samples from Ebola virus disease survivors, household contacts, and community controls, Sierra Leone, 2015
Sensitivity (proportion of Kerry Town 
survivors reactive on test)
Specificity (proportion of community 
controls unreactive on test)
n/N % (95% CI) n/N % (95% CI)
Single test 113/116 97·4% (92·6–99·5) 338/339 99·7% (98·4–99·99)
Confirmed 93/97 95·9% (89·8–98·9) 339/339 100% (98·9–100)
Results are presented on the basis of a single test, and using the rule that all reactive results should be confirmed by a 
second test.
Table 2: Sensitivity and specificity of the oral fluid Ebola virus antibody test
See Online for appendix
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Asymptomatic Any symptoms
Total (n) IgG positive Total (n) IgG positive
n % (95% CI) p n % (95% CI) p
Total 389 10 2·6% (1·2–4·8) 92 11 12·0% (6·1–20·4)
Sex
Male 161 3 1·9% (0·0–5·3) 0·53 46 6 13·0% (4·9–26·3) 1·0
Female 228 7 3·1% (1·2–6·2) 46 5 10·9% (3·6–23·6)
Age (years)
<2 27 0 0·0% (0·0–12·8) 0·11 3 1 33·3% (0·8–90·6) 0·001
2–4 43 0 0·0% (0·0–8·2) 0·06 (trend) 12 3 25·0% (5·5–57·2)
5–9 76 0 0·0% (0·0–4·7) 18 1 5·6% (0·1–27·3)
10–14 73 4 5·5% (1·5–13·4) 14 0 0·0% (0·0–23·2)
15–19 52 1 1·9% (0·0–10·3) 7 0 0·0% (0·0–41·0)
20–29 67 2 3·0% (0·4–10·4) 21 0 0·0% (0·0–16·1)
30–39 25 2 8·0% (1·0–26·0) 9 2 22·2% (2·8–60·1)
40–49 11 1 9·1% (0·2–41·3) 5 2 40·0% (5·3–85·3)
≥50 14 0 0·0% (0·0–23·2) 3 2 66·7% (9·4–99·2)
Maximum exposure
Handled corpse 10 2 20·0% (2·5–55·6) 0·003 2 2 100·0% (15·8–100) 0·06
Handled fluids 39 4 10·3% (2·9–24·2) 0·06 (trend) 17 1 5·9% (0·1–28·7)
Direct wet contact 120 1 0·83% (0·0–4·6) 41 6 14·6% (5·6–29·2)
Direct dry contact 68 0 0·0% (0·0–5·3) 13 1 7·7% (0·2–36·0)
Indirect wet contact 11 0 0·0% (0·0–2·9) 2 0 0·0% (0·0–84·2)
Indirect dry contact 52 1 1·9% (0·0–10·3) 11 0 0·0% (0·0–28·5)
Minimal or no contact 89 2 2·2% (0·3–7·9) 6 1 16·7% (0·4–64·1)
Occupation
Unemployed or child 282 4 1·4% (0·4–3·6) 0·10 62 6 9·7% (3·6–19·9) 0·004
Health-care worker 9 0 0·0% (0·0–33·6) 1 0 0·0% (0·0–97·5)
Manual work 85 4 4·7% (1·3–11·6) 22 1 4·5% (0·1–22·8)
Non-manual work 10 1 10·0% (0·3–44·5) 6 4 66·7% (22·3–95·7)
Status in household
Head 23 1 4·3% (0·1–22·0) 0·46 14 5 35·7% (12·8–64·9) 0·01
Member 366 9 2·5% (1·1–4·6) 78 6 7·7% (2·9–16·0)
Number of people in household
1–5 24 0 0·0% (0·0–14·3) 0·63 7 1 14·3% (0·4–57·9) 0·90
6–10 126 5 4·0% (1·3–9·0) 39 5 12·8% (4·3–27·4)
11–15 163 3 1·8% (3·8–5·3) 24 2 8·3% (1·0–27·0)
>16 76 2 2·6% (3·2–9·2) 22 3 13·6% (2·9–34·9)
Water available in household
Sometimes 78 0 0·0% (0·0–4·6) 0·31 7 0 0·0% (0·0–41·0) 0·89
Most days 125 3 2·4% (0·5–6·9) 27 3 11·1% (2·4–29·2)
Every day 183 6 3·3% (1·2–7·0) 58 8 13·8% (6·2–25·4)
Soap available in household
Sometimes 117 2 1·7% (0·2–6·0) 0·91 18 2 11·1% (1·4–34·7) 1·0
Most days 72 2 2·8% (0·3–9·7) 23 3 13·0% (2·8–33·6)
Every day 197 5 2·5% (0·8–5·8) 51 6 11·8% (4·4–23·9)
Latrine for household
Shared or none 228 5 2·2% (0·7–5·0) 1·0 71 9 12·7% (6·0–22·7) 0·52
Household’s own 158 4 2·5% (0·7–6·4) 21 2 9·5% (1·2–30·4)
Crowding (people per room)
High 89 3 3·4% (0·7–9·5) 0·68 25 4 16·0% (4·5–36·1) 0·16
Medium 253 5 2·0% (0·6–4·6) 60 5 8·3% (2·8–18·4)
Low 44 1 2·3% (0·1–12·0) 7 2 28·6% (3·7–71·0)
(Table 3 continues on next page)
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assuming seropositivity is a marker of Ebola virus 
infection, the ten asymptomatic and 11 symptomatic 
seropositive participants contributed 2·3% (ten of 427) 
and 2·6% (11 of 427) to Ebola virus infections, respectively. 
The contribution by age and exposure level is shown in 
figure 3 and appendix (p 9). In all age groups the 
proportion of infections that were asymptomatic was low, 
but it was higher in those aged 5–14 years (four [6·3%] 
of 64) than in those younger than 5 years (none [0%] of 53) 
and people aged 15 years or older (six [2·0%] of 307; 
p=0·07). The proportion of undiagnosed symptomatic 
infections was higher in those younger than 5 years 
(four [7·5%] of 53) than in those aged 5–14 years 
(one [1·6%] of 64) and those aged 15 years or older 
(six [2·0%] of 307; p=0·07).
Among those with positive tests, the NOD was similar 
in survivors and in those with asymptomatic (p=0·9) or 
missed symptomatic infections (p=0·7) in Wilcoxon 
rank-sum tests (appendix p 6).
Among survivors, no relation was seen between the 
magnitude of the NOD and the length of time since 
admission (appendix p 7) but the NOD was higher at 
younger ages (r²=0·08, p<0·001; appendix p 8).
Discussion
The oral fluid IgG capture ELISA performed well in this 
field setting. The oral swabs were accepted by the 
population (only 1% refused) and were suitable for 
children and adults. The swabs required no processing 
before storage at –20°C, making them easy to use in field 
conditions. We optimised specificity by using a high 
cutoff (figure 2) and requiring two reactive results to 
confirm a positive; sensitivity remained high (95·9%).
Using this assay, 2·6% (ten of 388) of asymptomatic 
members of Ebola-affected households had evidence of 
Ebola virus infection. This result is lower than some 
household contact studies, but few such studies restricted 
examination to asymptomatic contacts, different assays 
were used, and the definition of contact varied. Excluding 
any symptomatic individuals, previous estimates 
were 2·5% (ten of 404) in Yambuku, Democratic Republic 
of the Congo, using an immunofluorescence assay;16 
4·0% (four of 101) in Kikwit;17 21·4% (12 of 56) in Gabon;18 
45·9% (11 of 24) among highly exposed contacts in 
Gabon;4 1·0% (two of 210) in Uganda,3 and 6·5% 
(12 of 185) in Kono, Sierra Leone,19 using different 
ELISAs. A preliminary report from Liberia studied 
760 household members or sexual contacts; 13% were 
positive but it is not clear if all were asymptomatic or to 
which contact group they belonged.20
The higher proportion of asymptomatic infection in 
adolescents, and the higher reactivity levels in younger 
survivors are consistent with a lower risk of severe 
disease. Immunological differences between sympto-
matic and asymptomatically infected individuals, and 
between adults and children, have been noted 
previously.17,21,22 The slight excess of missed symptomatic 
infections in children younger than 5 years is consistent 
with underdiagnosis in this group.11 There was no 
evidence that any of the seropositive results were due to 
late transmission via semen:23 only two spouses of EVD 
survivors were seropositive and both were male.
WHO guidelines for EVD survivor care24 suggest that a 
positive IgG test could help define survivors if certificates 
(issued on discharge from a treatment centre) are missing, 
so a highly specific test is essential. An acceptable, sensitive, 
and specific assay would also assist vaccine studies, where 
knowledge of pre-existing immunity is important, and in 
identifying previously undiagnosed EVD cases who might 
have played a crucial part in transmission.
Testing the sensitivity assumed the Kerry Town 
survivors were correctly diagnosed. All four seronegative 
Kerry Town survivors were documented PCR-positive 
before admission; after admission, two (including the 
one with reactivity near the cutoff) had high-level PCR 
results, one had two low-level PCR results, and for the 
Asymptomatic Any symptoms
Total (n) IgG positive Total (n) IgG positive
n % (95% CI) p n % (95% CI) p
(Continued from previous page)
Spouse Ebola survivor
No 372 10 2·7% (1·3–4·9) 1·0 86 9 10·5% (4·9–18·9) 0·15
Yes 17 0 0·0% (0·0–19·5) 6 2 33·3% (4·3–77·7)
Household quarantined
No 62 1 1·6% (0·0–8·7) 0·18 9 1 11·1% (0·3–48·2) 0·45
Yes 302 7 2·3% (0·9–4·7) 71 10 14·1% (7·0–24·4)
Unknown 25 2 8·0% (1·0–26·0) 12 0 0·0% (0·0–26·5)
p values from Fisher’s exact test for heterogeneity are presented for all variables. p values from a non-parametric test for trend across ordered groups (an extension of the 
Wilcoxon rank-sum test) are presented where the proportions suggest a trend. In this table, the one sample from an asymptomatic individual with an indeterminate result 
was taken as negative. Age was missing for one person, occupation for four, household characteristics (water, soap, latrine and crowding) for three, and quarantine for 37.
Table 3: Prevalence of Ebola IgG positivity in asymptomatic and symptomatic household members of Ebola virus disease survivors, Sierra Leone, 2015, 
by individual and household characteristics
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one with the lowest reactivity (appendix p 5), who was 
aged in her 80s, we have no post-admission record of 
positive PCR results. Oral fluid containing insufficient 
IgG will fail to signal; this can only be checked by 
determining IgG concentrations, which was not available 
in this setting. We did not have paired serum samples 
from these individuals, though good correlation with oral 
fluid results has been shown previously.
The oral fluid samples were collected up to 10 months 
after exposure. A reduction in IgG concentrations is 
possible, though antibody persistence for several years 
has been noted previously,17,25,26 and we found no evidence 
of a reduction (appendix p 7). It is theoretically possible 
that low level infections might have led to low 
concentrations of IgG that were not detected, which 
would underestimate the proportion of asymptomatic 
infections. However, in our study, above the cutoff, the 
NOD was similar in those with asymptomatic infection 
and in survivors (appendix p 6). We did not have enough 
test kits to re-test all those with initially unreactive 
results, but all 119 tested in duplicate remained 
unreactive.
Because our initial contact was through the community 
re-integration team, we only investigated survivor house-
holds. Survivors might be less infectious than those who 
die,12,27–29 but 70% of households in the study had at least 
one EVD death and exposure levels were high: 47·6% 
(229 of 481) of household contacts without diagnosed EVD 
reported contact with corpses, body fluids, or wet cases, 
yet only 7·0% (16 of 229) of these were infected.
Accurate recall of symptoms is difficult. Forgetting or 
reluctance to admit previously unreported symptoms 
might overestimate the incidence of asymptomatic 
infection. Conversely, being in an EVD-affected house-
hold might have led to over-reporting of symptoms. 
During interviews family members would contribute 
details of the exposure and health of others, probably 
increasing recall accuracy.
In conclusion, we have used a non-invasive assay to 
show that asymptomatic Ebola virus infection occurs, but 
accounted for only a small proportion of infections, so 
would have little effect on herd immunity. It is unknown 
whether those with asymptomatic Ebola virus infection 
are infectious, or could harbour virus in the long term, 
like some survivors. In that respect, the low proportion of 
asymptomatic infections is reassuring because these 
transmissions would be challenging to prevent. We also 
identified missed symptomatic cases, some of which 
were mild. Many questions remain, including why some 
people escape infection or disease despite high exposure, 
and whether those asympto matically infected will have 
any immunity in future outbreaks.
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Figure 3: Ebola manifestation and risk in households of survivors of Ebola virus disease (A) by age group in all 
members and (B) by exposure level (excluding the primary cases in each household)
The primary cases were excluded for (B) so that the outcomes for each type of contact in Ebola-affected 
households could be seen. Information on deceased household members was provided at interview by the 
surviving household members. Exposure levels were determined from the interviews with all household members. 
Exposure levels are defined as follows: corpse, touched body of someone who died of EVD; fluids, direct contact 
with body fluids of a wet case (ie, an EVD case with diarrhoea, vomiting, or bleeding); direct wet, direct contact 
with a wet case (including nursing and personal care, sharing a bed, breastfeeding an EVD-positive child); direct 
dry, direct contact with a dry case (ie, an EVD case without wet symptoms); indirect wet, indirect contact with a 
wet case (eg, washing clothes or bed linen); indirect dry, indirect contact with a dry case; minimal or none, minimal 
contact (eg, shared meals) or no known contact. See Bower and colleagues12 for details. EVD=Ebola virus disease.
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